ArticleJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2009
Refractory restless legs syndrome likely caused by olanzapine.
Article in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 29 citations in OpenAlex.
- Restless Legs Syndrome and the Use of Antipsychotic Medication: An Updated Literature Review.Cureus · 2022Review
- Olanzapine-induced restless leg syndrome (Willis-Ekbom disease): A case report.SAGE open medical case reports · 2022Article
- Article
- Medications associated with restless legs syndrome: a case-control study in the US Renal Data System (USRDS).Sleep medicine · 2014Article
- Addressing sleep disturbances: an opportunity to prevent cardiometabolic disease?International review of psychiatry (Abingdon, England) · 2014Review
- Integrating sleep management into clinical practice.Journal of clinical psychology in medical settings · 2012Article
- Restless legs syndrome due to aripiprazole.European journal of clinical pharmacology · 2011Article
- Olanzapine-induced restless leg syndrome: a case report and review of literature.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of severe restless legs syndrome (RLS) that occurred as a side effect of olanzapine therapy. It was refractory to treatment with 2 mg of clonazepam and 3 mg ropinirole. There was partial relief with propoxyphene, however, it was stopped because of side effects. The symptoms disappeared once olanzapine was switched to another antipsychotic medication. Only two prior published reports associate olanzapine usage with development of RLS. In one report, low-dose benzodiazepines and ropinirole were associated with resolution of RLS symptoms stating dopamine depletion as the likely etiology. In our patient, however, RLS due to olanzapine was refractory to the trial of both high-dose benzodiazepine and ropinirole. This suggests that RLS occurring as a side effect of olanzapine therapy may have additional causative mechanisms beyond simple dopamine depletion as postulated before. High-dose narcotics, if tolerated, may be an alternative in such refractory cases.
Indexed as
Identifiers
19317385PMC2637170W18095031What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.